New Fluoroquinolone Warning

• Autores: Rebecca Voelker
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 23, 2016, pág. 2514
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Patients with sinusitis, bronchitis, and uncomplicated urinary tract infections (UTIs) should receive fluoroquinolone antibacterial drugs only if other treatment options aren’t available, the FDA has advised.

    In a Drug Safety Communication, the agency warned that systemic fluoroquinolones are associated with disabling and potentially permanent adverse effects involving tendons, muscles, nerves, and the central nervous system.